7月14日，礼来盘中下跌3.11%，报1147.74美元/股，成交额7.52亿美元。
消息面上，联邦上诉法院当日重启礼来专利诉讼，梯瓦制药主张礼来依托新增独家销售权人为阻碍仿制药上市，损害其合法经营权益，仿制药上市争议再度发酵，引发市场对礼来部分产品专利壁垒的担忧。此外，生物医药板块近一个月累计涨幅达25%后集中获利了结，同日制药行业整体承压，强生跌1.51%、默沙东跌2.39%、阿斯利康跌1.94%，板块轮动亦对礼来构成拖累。此前礼来曾于7月7日股价触及1249美元历史新高，短期回调压力释放。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.